Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 18/20 | 0.65 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30297347 | 1.00 | P2RX4 (0.65) | P2RX4STK39GAA | |
| SCHEMBL16239063 | 0.94 | P2RX4 (0.69) | P2RX4GAA | |
| SCHEMBL16239197 | 0.92 | P2RX4 (0.73) | P2RX4 | |
| SCHEMBL30297423 | 0.92 | P2RX4 (0.73) | P2RX4 | |
| SCHEMBL30297242 | 0.91 | P2RX4 (0.65) | P2RX4 | |
| SCHEMBL30297230 | 0.91 | P2RX4 (0.65) | P2RX4GAA | |
| SCHEMBL16239105 | 0.91 | P2RX4 (0.65) | P2RX4GAA | |
| SCHEMBL16238923 | 0.91 | P2RX4 (0.65) | P2RX4 | |
| SCHEMBL30297265 | 0.90 | P2RX4 (0.64) | P2RX4GAA | |
| SCHEMBL16239184 | 0.90 | P2RX4 (0.64) | P2RX4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | claimed |
| US-20250375456-A1 | AGENT FOR PREVENTING OR TREATING RESPIRATORY DISEASE | NIPPON CHEMIPHAR CO (JP) | 2025-12-11 | — | — | US | claimed |
| US-20250241927-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | NIPPON CHEMIPHAR CO (JP) | 2025-07-31 | — | — | US | claimed |
| EP-4501357-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | Takasaki University of Health and Welfare (JP) | 2025-02-05 | — | — | EP | claimed |
| WO-2024177158-A1 | SOLID DISPERSION OF COMPOUND HAVING P2X4 RECEPTOR ANTAGONISM | 日本ケミファ株式会社 | 2024-08-29 | — | — | WO | claimed |
| EP-4410310-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR RESPIRATORY DISEASES | Nippon Chemiphar Co., Ltd. (JP) | 2024-08-07 | — | — | EP | claimed |
| US-11918589-B2 | Medicament for treatment of multiple sclerosis | NIPPON CHEMIPHAR CO., LTD. (JP) | 2024-03-05 | — | — | US | claimed |
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | claimed |
| US-20230277552-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-09-07 | — | — | US | claimed |
| WO-2023157895-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR ENDOMETRIOSIS OR ADENOMYOSIS | 国立大学法人 鳥取大学 | 2023-08-24 | — | — | WO | claimed |
| EP-4190356-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOMS ASSOCIATED WITH ALLERGIC REACTION | Nippon Chemiphar Co., Ltd. (JP) | 2023-06-07 | — | — | EP | claimed |
| US-20230149421-A1 | MEDICAMENT FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-05-18 | — | — | US | claimed |
| WO-2023054578-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR RESPIRATORY DISEASES | 日本ケミファ株式会社 | 2023-04-06 | — | — | WO | claimed |
| EP-4129296-A1 | DRUG FOR PREVENTION OR TREATMENT OF IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | Università di Pisa (IT) | 2023-02-08 | — | — | EP | claimed |
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | claimed |
| EP-3848051-A1 | MEDICINE FOR DIABETIC PERIPHERAL NEUROPATHY | Nippon Chemiphar Co., Ltd. (JP) | 2021-07-14 | — | — | EP | claimed |
| US-20210121478-A1 | MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2021-04-29 | — | — | US | claimed |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-07-16 | — | — | US | claimed |
| EP-2803662-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2017-03-01 | — | — | EP | claimed |
| US-9382236-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2016-07-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375456-A1 | AGENT FOR PREVENTING OR TREATING RESPIRATORY DISEASE | P2RX5, P2RX3, P2RX2 | P2RX4 7/4885STK39 2429/4885GAA 2190/4885 |
| US-20210121478-A1 | MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS | TRPM4, TRPM7, P2RX3 | P2RX4 5/4885STK39 2029/4885GAA 2938/4885 |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885STK39 3328/4885GAA 4772/4885 |
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885STK39 3328/4885GAA 4772/4885 |
| US-11918589-B2 | Medicament for treatment of multiple sclerosis | P2RX3, TRPM4, P2RX4 | P2RX4 3/4885STK39 2147/4885GAA 2990/4885 |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TRPV1, TRPV4, TRPV5 | P2RX4 15/4885STK39 2185/4885GAA 1352/4885 |
| US-20230277552-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION | P2RX5, P2RX3, P2RX2 | P2RX4 4/4885STK39 1305/4885GAA 1523/4885 |
| US-20230149421-A1 | MEDICAMENT FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | P2RX5, P2RX3, P2RX2 | P2RX4 5/4885STK39 1336/4885GAA 3147/4885 |
| US-20250241927-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | P2RX3, TRPV1, P2RX2 | P2RX4 5/4885STK39 2471/4885GAA 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.